p21Waf1/Cip1 as a therapeutic target in breast and other cancers.
about
Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance.Pathway analysis of kidney cancer using proteomics and metabolic profilingThe role of p21 in regulating mammalian regenerationDCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinomaMechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemiaSomatic cell type specific gene transfer reveals a tumor-promoting function for p21(Waf1/Cip1)TNF-alpha-mediated apoptosis in vascular smooth muscle cells requires p73Heterogeneity of mammary lesions represent molecular differencesp21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levelsHomozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancerSerum-nutrient starvation induces cell death mediated by Bax and Puma that is counteracted by p21 and unmasked by Bcl-x(L) inhibition.Acetonic extract of Buxus sempervirens induces cell cycle arrest, apoptosis and autophagy in breast cancer cellsSynthesis, antimitotic and antivascular activity of 1-(3',4',5'-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles.p21 as a transcriptional co-repressor of S-phase and mitotic control genesInduction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia.Cell cycle regulation by the PRMT6 arginine methyltransferase through repression of cyclin-dependent kinase inhibitors.Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 proteinp21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1.Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer.Grape seed extract upregulates p21 (Cip1) through redox-mediated activation of ERK1/2 and posttranscriptional regulation leading to cell cycle arrest in colon carcinoma HT29 cells.Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage.The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation.Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanismsOverexpression p21WAF1/CIP1 in suppressing retinal pigment epithelial cells and progression of proliferative vitreoretinopathy via inhibition CDK2 and cyclin EActivin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancermiR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: a potential for therapeutic intervention.Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.Altering cancer transcriptomes using epigenomic inhibitorsCholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathway.β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells.Role for histone deacetylase 1 in human tumor cell proliferationModeling resistance to pathway-targeted therapy in ovarian cancerThe activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivoTargeting cancer by binding iron: Dissecting cellular signaling pathwaysThe dual function of PRMT1 in modulating epithelial-mesenchymal transition and cellular senescence in breast cancer cells through regulation of ZEB1Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types.From bead to flask: Synthesis of a complex β-amido-amide for probe-development studies.A novel p21 attenuator which is structurally related to sorafenib.Fangchinoline induces G0/G1 arrest by modulating the expression of CDKN1A and CCND2 in K562 human chronic myelogenous leukemia cells.p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.
P2860
Q21093282-F9DC1041-762B-4F52-B588-F385E12192EBQ21245737-EF6B7537-498E-450A-AB4F-D8ACC18C0B18Q28242137-09CD4AD7-DE70-493B-A5A0-D9264E1DDCA1Q28297100-19249906-D22F-4022-AFB9-2594BBA48473Q28385690-23E81CBA-D426-4590-8F1D-68A37F0A2A20Q28513336-E3FF263D-2ED9-4728-9CE9-FE2FCBA99AF0Q28579894-9682F4A4-4D57-4A6C-BF7F-99C26949525FQ33265521-A31A1967-E346-4D17-BA08-490D45CA0ED2Q33294928-ED0705BC-EC25-429E-85FF-A2294F52DC0EQ33718622-987C0624-A451-47EF-8358-7BF8AC2BE8F7Q34009416-72E26BC8-A52B-4F8F-970A-4390D8A37D0CQ34026139-6E811376-C33A-4A3A-9183-0C6C94A6CF95Q34155028-7EC37781-6920-4377-B1CC-36B6EAE8F2CFQ34291251-D7779E3D-D841-4539-BFC5-251DDD1C7E6CQ34338550-1FF91AA7-02FD-4C82-A797-AA7392A1C28DQ34390742-7966CFDD-C7D7-4074-AD05-330B183E5716Q34583585-FEE926CA-4863-4642-AF22-04C827AD34F0Q34685574-E5E835D2-A087-4E6D-8233-8920CA24A292Q34756265-55D71931-70F2-4E7A-86FC-D23C8B9D864AQ35032457-386A4454-4BF8-493E-97E4-53161A3FA639Q35302120-A2F22FFA-4498-44C9-90F4-FE7C46390018Q35371834-227DDCAB-98D9-4DA5-92A0-FA740E29AAACQ35426181-77FD28E8-C973-41B9-A945-581EBF77A412Q35447625-A1E871AB-C063-4E18-8489-6F5B4B85A6CDQ35527116-34003E97-7909-4454-ABA0-4E626A00F369Q35559007-309ED7C0-B6AB-4A72-9DBC-78B9FFC12F44Q35657936-313B4EAB-049E-473C-BC80-F71BC68AE5E6Q35863203-FEF0556E-F39C-414C-8E07-DAD8DC413767Q35925314-3B316E24-3D21-44CD-A47B-2EFCB702640CQ35930626-97D3C01B-793B-46B5-827A-A90EC9064AC4Q35948150-2AD39CF6-A5D2-4EBA-A659-08876C3722C7Q36170527-63B0F5E6-AA8D-4898-80DD-08309890F9F6Q36291117-565DA823-C2D7-46F1-AC66-7B70F432ACD8Q36326247-C5C63CB1-D095-49C9-9AF2-A9AA3D226624Q36507087-4472AE24-90AB-43EF-A141-B4A4E409EC1CQ36557412-B2B8EE44-721F-4424-A89D-D49A0321932EQ36594203-262AFC0B-5F91-43F4-AA31-38270C5B87D0Q36677729-E9AF0784-FD30-4A14-8D81-4CC630E16741Q36769047-C1EE8194-0DDA-472E-921F-A885C88473E0Q36781240-D878FFD0-C0EB-46E1-A0D4-2C9055C44B57
P2860
p21Waf1/Cip1 as a therapeutic target in breast and other cancers.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
p21Waf1/Cip1 as a therapeutic target in breast and other cancers.
@ast
p21Waf1/Cip1 as a therapeutic target in breast and other cancers.
@en
type
label
p21Waf1/Cip1 as a therapeutic target in breast and other cancers.
@ast
p21Waf1/Cip1 as a therapeutic target in breast and other cancers.
@en
prefLabel
p21Waf1/Cip1 as a therapeutic target in breast and other cancers.
@ast
p21Waf1/Cip1 as a therapeutic target in breast and other cancers.
@en
P1433
P1476
p21Waf1/Cip1 as a therapeutic target in breast and other cancers.
@en
P2093
Robert H Weiss
P304
P356
10.1016/S1535-6108(03)00308-8
P577
2003-12-01T00:00:00Z